Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study

作者：Zhe Liu, Qin Wang, Na Li, Chunyu Xu, Yunpu Li, Jun Zhou, Liu Liu, Haijing Zhang, Yang Mo, Feng Han, Dongqun Xu · 发表于：Frontiers in Public Health · 年份：2023 · DOI：10.3389/fpubh.2022.1082327 · 被引用次数：7 · 研究领域：Air Quality and Health Impacts、Climate Change and Health Impacts、Air Quality Monitoring and Forecasting

Background Exposure to PM 2.5 will accelerate the progression of cardiovascular diseases. Air purifier can reduce the PM 2.5 exposure and theoretically alleviate the influence of PM 2.5 on patients with stable coronary artery disease (SCAD). However, few studies of the protective effect showed significant results because the interferent effects of routine medication had not been taken into account. In order to explore the actual effect on patients with SCAD, we conducted a randomized single-blind crossover air purifier intervention trial. Method Levels of PM 2.5 exposure during intervention and cardiovascular indicators (inflammation, coagulation, plaque stability, and blood lipids) after intervention were detected, meanwhile the information of drug use was obtained by questionnaire. The kinds of drug used by more than 20% of the subjects were sorted out. And the influence of these drugs on cardiovascular indicators was summarized through literature review. Based on that, the drug use was included as a variable in linear mixed effects models that used to analyze the associations between PM 2.5 exposure reduction by air purifier and cardiovascular indicators. Results The result revealed that the interpretation contribution rate of drug use was more than that of PM 2.5 exposure. The level of C-reactive protein significantly decreased by 20.93% (95%CI: 6.56%, 33.10%), 23.44% (95%CI: 2.77%, 39.39%) and 24.11% (95%CI: 4.21%, 39.69%) on lag1, lag01 and lag02 respectively, while the...